Somatic Cell Gene Therapy

I've drafted an initial article on Somatic Cell Gene Therapy. Please review.

Review by Critic Carla:

The article is well-written, maintains a professional encyclopedic tone, and is accurately focused on the topic of Somatic Cell Gene Therapy. The lead section is substantial and provides a clear distinction between somatic and germline therapy.

However, there are a few areas where the article could be strengthened to meet high editorial standards:

• Expand the "Notable Contributors" section of the infobox. Currently, this is listed as "Not specified." Given the detailed historical section, the editor should add key figures such as W. French Anderson (mentioned in the references) or Jennifer Doudna and Emmanuelle Charpentier to the infobox for quick reference.
• Improve the formatting of the "Delivery Methods" lists. The viral and non-viral vector sections are currently formatted as single-item bullet points within separate paragraphs. These should be consolidated into a single, cohesive list or converted into subsections for better readability and structural consistency.
• Add a dedicated "Ethics" section. While the lead section briefly mentions that SCGT avoids the "designer baby" controversy, a full encyclopedia article should have a standalone section discussing the ethical nuances of SCGT, such as the high cost of treatment (equity of access) and the risks of off-target effects.
• Clarify the Jesse Gelsinger case. In the "Historical Development" section, the article attributes the 1999 setback to a trial for X-SCID. Jesse Gelsinger was actually part of an ornithine transcarbamylase (OTC) deficiency trial. The editor must correct this factual error to maintain scientific accuracy.

Fact-check by Fact-Checker Finn:

• Factual Error: The article incorrectly attributes the death of Jesse Gelsinger to a trial for X-linked severe combined immunodeficiency (X-SCID). Jesse Gelsinger died in 1999 during a clinical trial for Ornithine Transcarbamylase (OTC) deficiency.
• Missing Nuance: The claim that SCGT "avoids" ethical concerns associated with "designer babies" is an oversimplification. While it avoids germline transmission, somatic editing still raises significant ethical debates regarding equity, enhancement versus therapy, and unintended off-target effects.
• Vague/Unsupported Claim: The statement that SCGT "aims to treat the root cause... rather than merely managing the symptoms" is presented as a general fact, but many current SCGT applications provide functional protein supplementation without actually "correcting" the endogenous mutated gene.
• Absolute Language: The phrase "making it a widely accepted frontier" is non-neutral and promotional; "widely accepted" lacks a metric or citation to define the scope of this acceptance.

Review complete. Some issues were flagged. @Scientist Sage, please address the feedback.